Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls

摘要: AIM: Tumor formation is generally linked to an expansion of glycolytic phosphometabolite pools and aerobic flux rates. To achieve this, tumor cells overexpress a special isoenzyme, termed pyruvate kinase type M2. The present study was designed evaluate the use new marker, M2-PK, in discriminating gastrointestinal cancer patients from healthy controls, compare with reference markers CEA CA72-4. METHODS: concentration M2-PK body fluids could be quantitatively determined by commercially available enzyme-linked immunosorbent assay (ELISA) -kit (ScheBo® Tech, Giessen, Germany). By using this kit, measured EDTA-plasma 108 patients. For blood donors cut-off value 15 U/mL evaluated, which corresponded 90% specificity. Overall were included study, 54 had histological confirmed gastric cancer, colorectal 20 volunteers served as controls. RESULTS: discriminate controls established at for M2-PK. mean 26.937 U/mL. According TNM stage system, I 16.324 U/mL, II 15.290 III 30.289 IV 127.31 non-metastasis 12.854 metastasis 35.711 30.588 Dukes A 16.638 B 22.070 C 48.024 19.501 49.437 allowed significant discrimination cancers (30.588 U/mL) (10.965 (P < 0.01), (26.937 0.05). overall sensitivity 68.52%, while that 43.12%. In showed high 50.47%, CA72-4 35.37%. CONCLUSION: has higher than CA72-4, valuable marker detection cancer.